Last updated on June 2020

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis


Brief description of study

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Clinical Study Identifier: NCT03773965

Find a site near you

Start Over

Centro Medico Privado de Reumatologia

San Miguel de Tucuman, Argentina
  Connect »

LKH Bregenz

Bregenz, Austria
  Connect »

AKH

Wien, Austria
  Connect »

UCL- Saint Luc

Bruxelles, Belgium
  Connect »

CHU de Nancy Hop D'Enfants de Brabois

Vandoeuvre Les Nancy Cedex, France
  Connect »

Center of Children`s Health

Moscow, Russian Federation
  Connect »

Great Ormond Street Hospital

Bloomsbury, United Kingdom
  Connect »

Universit tsklinikum Freiburg

Freiburg im Breisgau, Germany
  Connect »

Universit tsklinikum Freiburg

Freiburg im Breisgau, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.